Please send Leadcare® II information to my child's pediatrician LEADCARE EVENTS

Blood-lead testing has never been easier – waived test is convenient for patients & practitioners

In 1997, ESA, now a Magellan Biosciences business, introduced the first-generation LeadCare system – a moderately complex test. Although its CLIA status limited how many providers could adopt the test, where it was implemented, the LeadCare I system proved that point-of-care testing works to reach at-risk children who are missed by traditional prescription-based or send-out testing programs.

Wanting to expand the test to more community-based sites that serve at-risk populations – from mobile health clinics and Head Start programs, to WIC clinics and Federally Qualified Health Centers – the CDC partnered with ESA to develop a CLIA-waived version. In September 2006, the FDA cleared LeadCare II.

The award-winning LeadCare II system removes all the complications formerly associated with blood-lead testing – waiting days for lab results, spending precious staff time and resources trying to contact patients for critical follow-up care, or tracking down lab results for record-keeping, reporting, or compliance purposes. Its CLIA-waived status enables a paradigm shift in lead testing: practitioners can test, educate, and initiate follow-up actions if necessary – instantly, on the spot, and all in one visit during the routine well-child check-up. This approach is convenient and easy for the child, parent, and healthcare provider, and thus, it is the most-effective way to ensure that those at greatest risk for lead poisoning actually receive mandated lead tests. > Continue

Click for information on lead-poisoning programs by state LeadCare II

Page: [1] 2 3 4